day trader
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
AGEN Agenus
- 3.570
- -0.190-5.05%
Close Jan 24 16:00 ET
- 3.700
- +0.130+3.64%
Post 20:01 ET
84.29MMarket Cap-0.32P/E (TTM)
3.951High3.550Low373.07KVolume3.730Open3.760Pre Close1.39MTurnover1.60%Turnover RatioLossP/E (Static)23.61MShares19.68852wk High-0.29P/B83.11MFloat Cap2.50052wk Low--Dividend TTM23.28MShs Float8419.554Historical High--Div YieldTTM10.67%Amplitude2.500Historical Low3.738Avg Price1Lot Size
Agenus Stock Forum
Sign in to post a comment
$Agenus (AGEN.US)$
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Wednesday, 22nd January at 2:48 pm
• Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL's potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC).
• New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Pha...
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
Wednesday, 22nd January at 2:48 pm
• Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL's potential to enable chemo-free and non-operative approaches in colorectal cancer (CRC).
• New randomized Phase 2 results in over 230 patients with refractory MSS mCRC, consistent with Pha...
1
$Agenus (AGEN.US)$ Benzinga· 3 mins ago
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
$Agenus (AGEN.US)$
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
1 minute ago, 4:30 AM PST
Via BusinessWire
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
1 minute ago, 4:30 AM PST
Via BusinessWire
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...
1
$Agenus (AGEN.US)$
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...
$Agenus (AGEN.US)$
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...
1
$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...
$Agenus (AGEN.US)$ Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...
4
$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...
$Agenus (AGEN.US)$
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanc...
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
Agenus Inc. (NASDAQ: AGEN) has published a groundbreaking study in Cancer Discovery on botensilimab, their novel Fc-enhanced anti-CTLA-4 antibody. The study highlights botensilimab's effectiveness against treatment-resistant cancers, including those unresponsive to conventional immunotherapy. Key findings include:
1. Demonstrated activity across multiple cancer types
2. Unique Fc-enhanc...
1
No comment yet
Trending Stocks
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day
暴躁的韭菜 : F